MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting

EQS-News: MorphoSys AG


/ Key word: Conference





MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting...

Related Keywords

Chicago ,Illinois ,United States ,Germany ,Massachusetts ,Planegg ,Bayern ,Boston ,American ,Kaitlyn Nealy ,Thomas Biegi ,Julia Neugebauer ,American Society Of Clinical Oncology ,Corporate Affairs ,Nasdaq ,Twitter ,Lymphoma Society ,Constellation Pharmaceuticals Inc ,Linkedin ,Sys To Present New Phase ,Oral Presentation ,Clinical Oncology ,Efficacy Data ,Combination With Ruxolitinib ,Patients With ,Advanced Solid Tumors ,Vice President ,Global Head ,Markets ,